Company facts
- Industry
- Pharmaceutical Preparations
- Headquarters
- Newtown Square, Pennsylvania
- Most recent report
- 8-K, filed Oct 19, 2026
- Incorporated
- Delaware
- Filings on record
- 157 filings
- On EDGAR
- CIK 1868279
- Fiscal year ends
- December
- Filer status
- Emerging growth company
Financials 8 of 11
News 8 of 32
Prospectuses and Registrations 8 of 11
- 424B5 Prospectus supplement for an offering May 11, 2026
- S-8 Registration statement for an employee plan Mar 5, 2026
- 424B5 Prospectus supplement for an offering Jul 2, 2025
- 424B5 Prospectus supplement for an offering Jul 1, 2025
- S-8 Registration statement for an employee plan Mar 3, 2025
- S-3ASR Automatic shelf registration Feb 3, 2025
- S-8 Registration statement for an employee plan Feb 2, 2024
- 424B4 Final prospectus for an offering Jan 26, 2024
Proxies 4
Ownership 8 of 73
- SCHEDULE 13G Large holder reported a passive stake Oct 13, 2026
- SCHEDULE 13D/A Large holder reported an active stake, amended Oct 8, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 27, 2026
- 4 Insider reported a trade Jun 22, 2026
- 4 Insider reported a trade Jun 22, 2026
- 4 Insider reported a trade Jun 22, 2026
- 4 Insider reported a trade Jun 22, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended May 6, 2026
Other 8 of 26
- ARS Annual report sent to shareholders Apr 28, 2026
- ARS Annual report sent to shareholders Apr 28, 2025
- SEC STAFF LETTER Jan 26, 2024
- EFFECT Notice that a registration became effective Jan 25, 2024
- S-1MEF Jan 25, 2024
- CERT Exchange certified a listing Jan 25, 2024
- 8-A12B Registration of a security for exchange listing Jan 23, 2024
- CORRESP Reply to SEC staff Jan 23, 2024
Everything here comes from ArriVent BioPharma, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.